key: cord-0876431-ljudwwo4
authors: Appelman, Brent; Oppelaar, Jetta J.; Broeders, Lani; Wiersinga, Willem Joost; Peters-Sengers, Hessel; Vogt, Liffert
title: Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort
date: 2022-02-10
journal: Sci Rep
DOI: 10.1038/s41598-022-06276-7
sha: 27ab259e39fbf031e5a7b6394c56e6d10414ee3c
doc_id: 876431
cord_uid: ljudwwo4

Chronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.

Outcomes and statistical analyses. We compared comorbid risk factors, baseline vitals and laboratory values, and disease severity across groups. Parametric variables were presented as mean and standard deviation (SD); for non-parametric data, the median and interquartile range (IQR) was used. Dichotomous data were presented with frequencies (n) and percentages (%). To compare differences for continuous data, we used a one-way ANOVA or Kruskal-Wallis (KW) test, depending on the type of distribution. If the overall group was deemed significant, posthoc pairwise t-tests (after one-way ANOVA) or Wilcoxon rank tests (after KW) were performed (Benjamini-Hochberg (BH), adjusted) to compare no CKD to the CKD group. For categorical data, we used the Fisher exact test to compare group differences, with pairwise posthoc tests (BH adjusted) with the no CKD group if overall significant. The primary outcome was a composite endpoint of all-cause mortality, readmission or palliative hospital discharge in a 12-week follow-up period. Logistic regression was used to adjust the association between CKD groups and primary outcome in a stepwise procedure for the following confounders: age, sex, ethnicity, number of comorbidities, and designated COVID-19 treatment wave, reflective of the introduction of dexamethasone as a standard treatment regimen 12 . Overall, < 2% observations were missing, which were entirely considered at random and listwise omitted from the adjusted analyses. A P ≤ 0.05 was considered significant. Data analyses were performed with R (v3.6.1) 13 .

Of the 5153 hospitalized COVID-19 patients enrolled, 755 were excluded because the admission was a readmission of COVID-19, it concerned a transfer from another hospital or were lossed to follow-up. A total of 247 patients with CKD were excluded due to missing pre-admission creatinine values and incomplete CKD stage information ( Supplementary Fig. 1 ). In the remaining 4151 patients, 389 (9.4%) patients were labeled as CKD patients and 3762 (90.6%) patients as no-CKD patients. At admission, baseline characteristics between groups were significantly different for age, ethnicity, designated treatment wave and prevalence of registered comorbidities (Table 1 ). There were no significant differences in disease severity on admission as measured with MEWS, qSOFA and CRP levels (Tables 1, 2 ).

There were multiple significant different vital signs and laboratory values at admission (Table 2) . Admission diastolic blood pressure was lower in CKD stage 4 compared to no-CKD, while other vital parameters were not significantly different when comparing CKD groups to No CKD in post-hoc analyses. Hemoglobin levels were significantly lower in all CKD patients compared to no-CKD. Albumin was significantly lower in patients with CKD stage 3b and stage 4. The lymphocyte count and platelet count showed no significant difference between groups in post-hoc analyses. There were several other laboratory differences; a significant decrease of plasma sodium, increase of plasma potassium, lower plasma ALAT and lower pH in some of the CKD groups ( Table 2) . Most of these mean values were, however, within the normal range.

Mortality and readmission rates. A total of 996 patients (24.0%) died or were readmitted after 12 weeks of follow-up. In the unadjusted model, all CKD stages, except CKD stage 5, were associated with significantly higher mortality and readmission rate compared to no-CKD patients (Fig. 1a-c) . After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX, odds ratios of death and readmission were significantly different compared to patients without CKD and ranged from 1.96 to 8.94. All CKD patients combined showed a significantly increased unadjusted and adjusted mortality and readmission rate ( Supplementary Fig. 2a-c) . A subgroup analyses comparing only CKD groups indicated an increased mortality and readmission rate in patients with KTX in the adjusted model. (Supplementary Fig. 3a-c) .

Complications. We observed differences in the rate of congestive heart failure, anemia requiring transfusion and stroke in various stages of CKD compared to patients without CKD. Also, the self-reported incidence of cognitive decline was higher in patients with CKD stages 2 and 3b ( Table 3 ). All observed differences in complications were not significant in the post-hoc analyses; complications unlikely explained the higher mortality and readmission rate among CKD stages (Table 3 ).

Our multicenter cohort of admitted COVID-19 patients demonstrates overall increased mortality and readmission rates in patients with CKD. We show a strong unadjusted increased clinical mortality and readmission rate in patients with any form of CKD compared to patients without CKD, except for CKD stage 5. After full adjustments, in patients with CKD stages 3a, 3b, 4 and in KTX patients, the odds ratios remain significantly increased compared to patients without CKD. Notably, the odd ratios within CKD groups did not indicate any association www.nature.com/scientificreports/ www.nature.com/scientificreports/ with CKD stage severity. We could not identify the main complication responsible for the higher mortality and readmission rate. We also could not identify clear patterns in vital signs or laboratory values at admission that explain increased mortality and readmission rate across CKD groups in our cohort, aside from lower diastolic blood pressure (CKD stage 4) and significant differences in hemoglobin and albumin-the latter being presumably directly related to CKD stage rather than COVID-19. The lack of an apparent factor that explains worse 12-week outcomes underscores that CKD as such is a COVID-19 risk factor. However, some distinctions can be made, as we also analyzed mortality and readmission rates among CKD patients with dialysis and KTX. Our findings are in concordance with the ERACODA collaborative study, where a higher mortality rate was found among KTX and dialysis patients than data from the general population 4 . However, in contrast to KTX patients from our cohort, dialysis patients (predominantly hemodialysis) do not appear to have significantly higher mortality and readmission rates after adjusting for known covariates. The significantly higher mortality after correction demonstrates that mortality and readmission rates in the KTX group are not dependent on known COVID-19 risk factors such as older age, male sex and ethnicity 14, 15 . This is in contrast with our findings in dialysis patients in whom the worse 12-week outcomes to some extent seem to be explained by higher age and more prevalent comorbidities associated with worse COVID-19 outcomes in non-renal patients.

It has been suggested that COVID-19 associated mortality in patients with KTX is due to the immunosuppressive condition of patients, which leads to an inability to clear the SARS-CoV-2 infection 16 . Various studies have also shown a limited yield of SARS-CoV-2 vaccines in patients with a solid transplantation [16] [17] [18] . This study again emphasizes the present-day increased risk of mortality in patients with KTX. Besides KTX patients, usage of immune suppressive medication in other CKD groups was not significantly different from the no-CKD group in our cohort.

There are some potential drawbacks associated with our study. First, although we can draw conclusions on the influence of CKD on COVID-19 outcomes, the influence of CKD severity was studied based on eGFR staging only. We were not able to include albuminuria stage, which could affect CKD severity and its association with outcomes. Furthermore, due to requiring pre-admission creatinine values, we have excluded 247 CKD patients. However, we believe this selection provides a more accurate representation of mortality within CKD www.nature.com/scientificreports/ groups. We also did not study the impact of the primary diagnosis causing CKD on the course of COVID-19 because these data were not completely available. At last, there are differences in baseline characteristics and in designated COVID-19 treatment wave, which might have resulted in different treatment regimens among groups. Although we adjusted for potential confounders, there remains a possibility of an overestimation or underestimation of results. However, we do believe this only makes our results more applicable to general clinical conditions in hospitals.

Our study demonstrates a clinically significant increased mortality and readmission rate in patients with a history of CKD. While previous studies mainly highlighted increased mortality among dialysis and KTX patients, we also demonstrate a clear increased 12-week mortality and readmission rate of SARS-CoV-2 infected patients in nearly all CKD groups. Besides justified concerns for KTX patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.

The original study protocol and data dictionary will be made available to researchers upon request. Researchers willing to access the de-identified participant dataset should send a request to l.vogt@amsterdamumc.nl.

Requests for data will be evaluated, and access will depend on the informed consent and permission of legal research support of Amsterdam UMC. 

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review

Clinical characteristics of coronavirus disease 2019 in China

CKD is a key risk factor for COVID-19 mortality

COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration

Chronic kidney disease is a key risk factor for severe COVID-19: A call to action by the ERA-edta

Predicting mortality of individual patients with COVID-19: A multicentre Dutch cohort

Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine

CO-RADS-A categorical CT assessment scheme for patients with suspected COVID-19: Definition and evaluation

Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association

Dexamethasone in hospitalized patients with Covid-19

A Language and Environment for Statistical Computing. R Foundation for Statistical Computing

Factors associated with COVID-19-related death using OpenSAFELY

Host genetic factors determining COVID-19 susceptibility and severity

The impact of COVID-19 on kidney transplantation and the kidney transplant recipient-One year into the pandemic

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Occurrence of severe Covid-19 in vaccinated transplant patients

We would like to thank the COVIDPredict consortium (www. covid predi ct. org) for their efforts in providing patient data.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-06276-7.Correspondence and requests for materials should be addressed to L.V.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.